{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Administrative Structure', 'Table 4', 'Study Administrative Structure', 'Function', 'Responsible Organization', 'Study Operations Management', 'Medical Monitoring', 'Study Master File', 'Data Management', 'Clinical Supply Management', 'Quality Assurance Auditing', 'Biostatistics', 'Medical Writing', 'Laboratory Assessments', 'Electrocardiogram Collection, Review, and Analysis', 'Pharmacokinetic Sample Testing', 'Medical Monitor', 'Further details can be found in the Medical Monitoring Plan. In case of any urgent medical issue', 'contact:', 'Dissemination of Clinical Study Data', 'The results of the study should be reported within 1 year from the end of the clinical study.', 'Irrespective of the outcome, the Sponsor will submit to the EU database a summary of the results', 'of the clinical study within 1 year from the end of the clinical study. It shall be accompanied by a', 'summary written in a manner that is understandable to laypersons.', 'Quality Control and Quality Assurance', 'According to the Guidelines of GCP (CPMP/ICH/135/95),', 'is responsible for', 'implementing and maintaining quality assurance and quality control systems with written', 'standard operating procedures (SOPs). Quality control will be applied to each stage of data', 'handling.', 'The following steps will be taken to ensure the accuracy, consistency, completeness, and', 'reliability of the data:', 'Central laboratories for clinical laboratory parameters.', 'Center Initiation visit.', 'Early center visits post-enrollment.', 'Routine center monitoring.', 'Ongoing center communication and training.', '29 October 2019', '62']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Data management quality control checks.', 'Continuous data acquisition and cleaning.', 'Internal review of data.', 'Quality control check of the final clinical study report (CSR).', 'In addition, Sponsor and/or', 'may conduct periodic', 'audits of the study processes, including, but not limited to study center, central laboratories,', 'vendors, clinical database, and final CSR. When audits are conducted, access must be authorized', 'for all study related documents including medical history and concomitant medication', \"documentation to authorized Sponsor's representatives and regulatory authorities.\", 'Monitoring', 'Sponsor has engaged the services of a contract research organization,', 'to perform all', 'monitoring functions within this clinical study.', ',', 'monitors will work in accordance with', 'SOPs. The monitor will establish and maintain regular contact between the Investigator', 'and Sponsor.', 'The monitor will evaluate the competence of the study center, informing Sponsor about any', 'problems relating to facilities, technical equipment, or medical staff. During the study, the', 'monitor will check that written informed consent has been obtained from all subjects correctly', 'and that data are recorded correctly and completely. The monitor is also entitled to compare', 'entries in eCRFs with corresponding source data and to inform the Investigator of any errors or', 'omissions. The monitor will also assess and control adherence to the protocol and ICH/GCP', 'guidelines at the study center. The monitor will arrange for the supply of study treatment, ensure', 'proper study treatment dispensing/accountability, and appropriate storage conditions are', 'maintained.', 'Monitoring visits will be conducted according to all applicable regulatory requirements and', 'standards. Regular monitoring visits will be made to each center while subjects are enrolled in', 'the study.', 'During monitoring visits, all entries in the eCRFs will be compared with the original source', 'documents (source data verification). For the following and all other items, this check will be', '100%:', 'Subject identification number.', 'Subject consent obtained.', 'Subject eligibility criteria (inclusion and exclusion criteria).', 'Efficacy variables.', 'Safety variables.', 'Medical record of AE.', 'Data Management/Coding', '29 October 2019', '63']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Data generated within this clinical study will be handled according to the relevant SOPs of the', 'Data Management and Biostatistics departments of', '.', 'Electronic data capture will be used for this study, meaning that all eCRF data will be entered in', 'electronic forms at the study center. Data collection will be completed by authorized study center', 'staff designated by the Investigator. Appropriate training and security measures will be', 'completed with the Investigator and all authorized study center staff prior to the study being', 'initiated and any data being entered into the system for any study subjects.', 'All data must be entered in English. The eCRFs should always reflect the latest observations on', 'the subjects participating in the study. Therefore, the eCRFs are to be completed as soon as', \"possible during or after the subject's visit. To avoid inter-observer variability, every effort should\", 'be made to ensure that the same individual who made the initial baseline determinations', 'completes all efficacy and safety evaluations. The Investigator must verify that all data entries in', 'the eCRFs are accurate and correct. If some assessments are not done, or if certain information is', 'not available or not applicable or unknown, the Investigator should indicate this in the eCRF.', 'The Investigator will be required to electronically sign off on the clinical data.', 'The monitor will review the eCRFs and evaluate them for completeness and consistency. The', 'eCRF will be compared with the source documents to ensure that there are no discrepancies', 'between critical data. All entries, corrections and alterations are to be made by the responsible', 'Investigator or his/her designee. The monitor cannot enter data in the eCRFs. Once clinical data', 'of the eCRF have been submitted to the central server, corrections to the data fields will be audit', 'trailed, meaning that the reason for change, the name of the person who performed the change,', 'together with time and date will be logged. Roles and rights of the center staff responsible for', 'entering the clinical data into the eCRF will be determined in advance. If additional corrections', 'are needed, the responsible monitor or Data Manager will raise a query in the EDC application.', 'The appropriate study center staff will answer queries sent to the Investigator. This will be audit', 'trailed by the EDC application meaning that the name of investigational staff, time and date', 'stamp are captured.', 'The eCRF is essentially considered a data entry form and should not constitute the original (or', 'source) medical records unless otherwise specified. Source documents are all documents used by', \"the Investigator or hospital that relate to the subject's medical history, that verify the existence of\", \"the subject, the inclusion and exclusion criteria and all records covering the subject's\", 'participation in the study. They include but are not limited to laboratory notes, ECG results,', 'memoranda, pharmacy dispensing records, subject files, etc. Source data should be attributable,', 'legible, contemporaneous, original, accurate, and complete. Changes to source data should be', 'traceable, should not obscure the original entry, and should be explained if necessary (eg, via an', 'audit trail).', '29 October 2019', '64']\n\n###\n\n", "completion": "END"}